Scarica l'app Stockscreener
36.82
0.77%
0.28
Dopo l'orario di chiusura:
36.82
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$36.54
Aprire:
$36.98
Volume 24 ore:
478.91K
Relative Volume:
0.76
Capitalizzazione di mercato:
$2.19B
Reddito:
$45.48M
Utile/perdita netta:
$169.95M
Rapporto P/E:
14.05
EPS:
2.62
Flusso di cassa netto:
$230.85M
1 W Prestazione:
+0.57%
1M Prestazione:
-9.51%
6M Prestazione:
+2.51%
1 anno Prestazione:
+49.13%
Intervallo 1D:
$36.34
$37.43
Intervallo di 1 settimana:
$35.03
$40.07
Portata 52W:
$23.17
$48.89
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Confronta PTGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
36.82 | 2.19B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Therapeutics CFO Ali Asif reports stock sale - MSN
Protagonist Therapeutics chief medical officer sells shares for tax obligations - Investing.com India
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $53.78 - Defense World
Protagonist Therapeutics CFO Ali Asif reports stock sale By Investing.com - Investing.com South Africa
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 6.2%Time to Sell? - MarketBeat
Long Term Trading Analysis for (PTGX) - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Trading 8.9% HigherStill a Buy? - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $53.78 Consensus PT from Brokerages - MarketBeat
Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck (NASDAQ:PTGX) - Seeking Alpha
Protagonist Therapeutics announces executive role change By Investing.com - Investing.com Australia
Protagonist Therapeutics announces executive role change - Investing.com
Protagonist Therapeutics Appoints Newman Yeilding as Chief Scientific Officer, Grants Equity Awards - StockTitan
Protagonist Therapeutics Reports Granting of Inducement Awards - AccessWire
Protagonist Therapeutics (NASDAQ:PTGX) Trading Down 4.4%What's Next? - MarketBeat
Principal Financial Group Inc. Acquires 310,804 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Principal Financial Group Inc. Purchases 310,804 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Reduced by Jane Street Group LLC - MarketBeat
Jane Street Group LLC Decreases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Where are the Opportunities in (PTGX) - Stock Traders Daily
Franklin Resources Inc. Acquires 45,674 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 2.3%Here's Why - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Barclays PLC Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
HighTower Advisors LLC Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Wellington Management Group LLP Makes New $1.35 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - Batesville Daily Guard
Protagonist Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Teachers Retirement System of The State of Kentucky Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Y Intercept Hong Kong Ltd Trims Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
(PTGX) Trading Signals - Stock Traders Daily
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical trials - Investing.com
State Street Corp Boosts Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
XTX Topco Ltd Takes $666,000 Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics’ (PTGX) Buy Rating Reiterated at HC Wainwright - Defense World
Clear Street sets $63 target on Protagonist Therapeutics By Investing.com - Investing.com Canada
BNP Paribas Financial Markets Purchases 16,597 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
BTIG maintains shares target on Protagonist Therapeutics, cites trial By Investing.com - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Fmr LLC Grows Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist's Rusfertide Shows Breakthrough Results in Phase 2 PV Study: 54% Hit Key Treatment Goals - StockTitan
The Goldman Sachs Group Begins Coverage on Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Weiss Asset Management LP Makes New $2.81 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Point72 Asset Management L.P. Sells 694,862 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded at The Goldman Sachs Group - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by BMO Capital Markets - MarketBeat
BMO Capital Initiates Coverage of Protagonist Therapeutics (PTGX) with Outperform Recommendation - MSN
Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities - Yahoo Finance
Charles Schwab Investment Management Inc. Buys 39,850 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
(PTGX) Technical Data - Stock Traders Daily
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by RTW Investments LP - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by HighVista Strategies LLC - MarketBeat
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):